

**2ND AND 3RD LINE TREATMENT FOR HER2-POSITIVE METASTATIC BREAST  
SALES AT EX-MANUFACTURER PRICE  
U.S. DOLLARS BY PRODUCT, INCLUDING  
Q4 2012 – Q3 2014**

	2012	2013			
	Q4	Q1	Q2	Q3	Q4
Ixempra®	\$15,861,022	\$14,435,723	\$13,488,772	\$12,738,028	\$10,995,764
Kadcyla®		\$14,328,948	\$63,999,957	\$78,256,141	\$82,852,340
Perjeta®	\$34,208,377	\$43,543,924	\$49,544,835	\$52,681,394	\$88,655,837
Tykerb®	\$31,138,049	\$29,985,339	\$26,126,981	\$24,222,882	\$22,848,420
Xeloda®	\$181,756,871	\$176,843,700	\$188,358,662	\$188,073,550	\$198,774,706
<b>Total</b>	<b>\$262,964,319</b>	<b>\$279,137,634</b>	<b>\$341,519,207</b>	<b>\$355,971,995</b>	<b>\$404,127,067</b>
Ixempra®	6.0%	5.2%	3.9%	3.6%	2.7%
Kadcyla®		5.1%	18.7%	22.0%	20.5%
Perjeta®	13.0%	15.6%	14.5%	14.8%	21.9%
Tykerb®	11.8%	10.7%	7.7%	6.8%	5.7%
Xeloda®	69.1%	63.4%	55.2%	52.8%	49.2%
<b>Total</b>	<b>100.0%</b>	<b>100.0%</b>	<b>100.0%</b>	<b>100.0%</b>	<b>100.0%</b>

Notes & Sources:

<sup>1</sup> Excludes Herceptin®.

Kadcyla® is indicated as a single agent for the treatment of people with HER2-positive metastatic breast cancer with chemotherapy. See, e.g., Exhibit 2317. In contrast:

Xeloda® can be used to treat colon, rectal, and other cancers. See, e.g., Exhibit 2246.

Perjeta® received FDA approval for neoadjuvant breast cancer therapy. See, e.g., Exhibit 2211.

Tykerb® is used to treat breast cancer, but is prescribed with a second medicine (Xeloda® or Femara®). See, e.g., Exhibit 2218. (These assertions and sources can be found in the report.)

Includes brand and generic values.

Ixempra® includes brand IXEMPRA 10/2007 BMO, identified in field 'Product.'

Kadcyla® includes brand KADCYLA 02/2013 GTC, identified in field 'Product.'

Perjeta® includes brand PERJETA 06/2012 GTC, identified in field 'Product.'

Tykerb® includes brand TYKERB 03/2007 GSK, identified in field 'Product.'

Xeloda® includes brand XELODA 05/1998 GTC, identified in field 'Product,' and generic capecitabine, identified in field 'Product.'

Includes Xeloda® (capecitabine), which is indicated for use with Tykerb® (lapatinib) in second-line therapy. Excludes capecitabine (e.g., vinorelbine), which are indicated for the use of other cancers. See Exhibit 2218 and Exhibit 2343.

Values reflect field 'Sales \$'.

Percentage calculated as percent of quarterly total.

Products identified from Exhibit 2103 and Exhibit 2224.

Data from IMS Health.